Ovation Acquires Lundbeck's Antipsychotic Buronil
This article was originally published in The Pink Sheet Daily
Executive Summary
Gaining FDA approval of melperone and two other recently acquired products – the anti-epileptics Sabril (vigabatrin) and Frisium (clobazam) – is a top priority for Ovation. The company has built a portfolio of 11 "under-performing" CNS products in less than two years.
You may also be interested in...
Questcor Acthar Gel Has Mid-’07 Action Date For Infantile Spasms, But Ovation To Seek Same Claim
Ovation plans to submit vigabatrin for the same indication in the coming weeks.
US FDA Expands Drug Development Tool Qualification Program With ISTAND Pilot
ClinROs, artificial intelligence-based algorithms will be included in approval pathway. FDA is taking a crash course on new techniques for trial assessment thanks to COVID.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: